

TAE Life Sciences to launch cancer radiation therapy in South Korea

11 November 2022 | News

TLS's targeted radiation therapy is used for the treatment of difficult-to-treat cancers, such as brain, head and neck cancers and melanoma



US-based TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), has announced a partnership with HDX Corporation (HDX) to bring TLS's targeted radiation therapy to South Korea.

Under the terms of the partnership, HDX, a premier distributor of radiation therapy medical equipment and clinical services based in Seoul, will provide primary sales, marketing, services, and distribution channel for the TLS Alphabeam System, including radiation oncology equipment, software and boron target drugs in South Korea.

TLS will provide support and training to HDX and intends to work with HDX to develop a local-language training and clinical education base in the future.

"Our partnership with TAE Life Sciences underscores the global expansion of BNCT as a unique cancer treatment for difficult-to-treat cancers," Sang-Jin Jung, CEO of HDX.

Bruce Bauer, PhD, CEO of TAE Life Sciences said, "South Korea has a strong history in adoption of advanced radiation therapy solutions. Our cutting-edge Alphabeam System provides both an in-hospital neutron source technology and the boron target pharmaceuticals that are required for a comprehensive BNCT system."